STOCK TITAN
  1. Home
  2. News
  3. NUWE

Nuwellis Inc - NUWE STOCK NEWS

Welcome to our dedicated news page for Nuwellis (Ticker: NUWE), a resource for investors and traders seeking the latest updates and insights on Nuwellis.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Nuwellis's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Nuwellis's position in the market.

News
Nuwellis Announces Launch of Ultrafiltration Therapy Using Aquadex Smartflow® System at Henry Ford Health
Rhea-AI Summary
Nuwellis, Inc. (NUWE) collaborates with Henry Ford Health to offer ultrafiltration therapy to heart failure patients as part of the REVERSE-HF study. The Aquadex SmartFlow system aims to improve clinical outcomes for patients resistant to diuretics, potentially revolutionizing heart failure treatment. Nuwellis focuses on addressing the therapy needs of the expanding heart failure patient population while reducing overall healthcare costs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.42%
Tags
none
-
News
Late-Breaking Data Highlighting Benefits of Ultrafiltration Therapy Using the Aquadex System for Heart Failure Patients was Presented at the Technology and Heart Failure Therapeutics Conference
Rhea-AI Summary
Nuwellis, Inc. (NUWE) presents positive clinical data analysis from the AVOID-HF trial at the THT conference. Results show Aquadex System's superiority in reducing heart failure readmissions and predicting patient response. Ultrafiltration therapy outperformed intravenous diuretics, with fewer heart failure events and hospitalizations. AI and ML models identified top predictors for 90-day heart failure events, aiding in personalized treatment plans.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.58%
Tags
none
-
News
Nuwellis, Inc. Announces Fourth Quarter and Full Year 2023 Financial Results
Rhea-AI Summary
Nuwellis, Inc. (NUWE) reported strong financial results for Q4 and full year 2023, with record revenue, expanding margins, and growth in pediatric sales. The company achieved a 9% increase in Q4 revenue, reaching $2.6 million, and a 4% increase in full-year revenue, totaling $8.9 million. Fourth quarter pediatric revenue grew by 35% year over year, with a 28% increase in utilization and a 49% increase in console sales. Nuwellis added new products, including a 12 cm dELC catheter and the Quelimmune SCD pediatric device. The company also received FDA approval for Quelimmune, enhancing its pediatric portfolio. Nuwellis showcased new clinical data and hosted a symposium at the THT conference to present Aquadex system trials. Despite challenges in the first half of 2023, the company achieved 27% revenue growth in the second half. Nuwellis aims to build on its momentum in 2024 with new clinical applications and product introductions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-16.76%
Tags
earnings
News
Nuwellis, Inc. To Report Fourth Quarter and Full Year 2023 Financial Results on March 5, 2024
Rhea-AI Summary
Nuwellis, Inc. (NUWE) will release financial results for Q4 and full year 2023 on March 5, 2024. The company focuses on fluid overload solutions. A conference call and webcast will discuss financials and business updates.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.43%
Tags
conferences earnings
-
News
Nuwellis’ Distribution Partner, SeaStar Medical, Receives FDA Humanitarian Device Exemption for Pediatric Selective Cytopheretic Device Quelimmune™
Rhea-AI Summary
Nuwellis, Inc. announces FDA approval for SeaStar Medical's pediatric Selective Cytopheretic Device, Quelimmune, to treat acute kidney injury and sepsis in children, showing a 50% mortality rate reduction. Nuwellis plans targeted commercial launch activities in 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.23%
Tags
none
-
News
Nuwellis, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
Nuwellis, Inc. (NUWE) announced equity awards under its 2021 Inducement Plan for new employees. The awards include options to purchase 764 shares at $0.70 each, vesting over four years.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.43%
Tags
none
News
Nuwellis to Announce Late-Breaking Clinical Data and Host Satellite Symposium at Technology and Heart Failure Therapeutics Conference
Rhea-AI Summary
Nuwellis, Inc. (NUWE) to showcase its Aquadex SmartFlow system at THT 2024 conference, featuring presentations by key experts on new developments in aquapheresis and AI-assisted identification of super responders for heart failure management.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
16.67%
Tags
clinical trial
-
News
New Case Series Demonstrates Potential of Aquadex Therapy for End-Stage Liver Disease Patients with Fluid Overload
Rhea-AI Summary
Nuwellis, Inc. announces promising findings for Aquadex SmartFlow® system in treating fluid overload in end-stage liver disease patients. The new data demonstrates the potential value of aquapheresis therapy in removing excess fluid for patients who don't respond to diuretics, offering a new market opportunity for the company. The study shows positive results in treating patients with end-stage liver disease, including improved mobility, reduced frailty, and the potential to enhance their ability to receive a life-saving liver transplant.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.25%
Tags
none
-
News
Nuwellis Receives FDA Clearance for an Additional Dual Lumen Extended Length Peripheral Catheter
Rhea-AI Summary
Nuwellis, Inc. (Nasdaq: NUWE) has received FDA clearance for its specialty peripheral dual lumen extended length catheter (dELC), providing an alternative peripheral access for ultrafiltration therapy across a broad range of patient physiologies. The new 12 cm dELC offers the same features as the longer 16 cm option but eliminates the need for trimming when a shorter catheter is needed. The Aquadex system is proven to remove excess fluid from patients suffering from fluid overload who have not responded to conventional medical management, including diuretics. It is cleared by the FDA for use in adults and pediatric patients weighing 20 kg (44 lbs.) or more.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-14.49%
Tags
clinical trial
News
New Real-World Data Highlight the Clinical Benefits of Ultrafiltration Therapy with Hematocrit Monitoring for Pediatric Patients
Rhea-AI Summary
Nuwellis, Inc. (NUWE) announces new real-world data demonstrating the effectiveness of Aquadex® ultrafiltration therapy with continuous hematocrit monitoring for pediatric patients with fluid overload. The data, featured in Pediatric Nephrology, show successful treatment of small patients without complications, validating Aquadex as an effective treatment option for fluid overload.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Stock NUWE logo
Nuwellis Inc

Nasdaq:NUWE

NUWE Rankings

N/A Ranked by Market Cap
N/A Ranked by Stock Gains
N/A Ranked by Dividends

NUWE Stock Data

2.48M
6.79M
0.06%
3.14%
12.08%
Surgical and Medical Instrument Manufacturing
Manufacturing
Link
US
Eden Prairie

About NUWE

chf solutions is an early stage company focused on commercializing the aquadex flexflow system. our objective is to improve the quality of life for patients with heart failure and related conditions, such as fluid overload. at chf solutions, we are committed to the relentless pursuit of identifying and developing innovative solutions to address unmet clinical needs with the goal of benefiting patients, medical practitioners, and the broader healthcare community. if you are looking for a career where you can make difference we would like to hear from you. we are looking for highly skilled, highly motivated people who want to be part of a growing company where everything you do will matter. chf solutions is an equal opportunity/affirmative action employer committed to cultural diversity in the workplace.